Fresh off FerGene’s meltdown, David Meek takes over at Mirati with lead KRAS drug racing to an approval

In the insular world of biotech, a spectacular failure can sometimes stay on any executive’s record for a long time. But for David Meek, the man at the helm of FerGene’s recent implosion, two questionable exits made way for what could be an excellent rebound.